Fig. 1.

Imaging and therapy study design. NOD-SCID Gamma (NSG) mice were injected with human myeloma cell lines, MM.1S-CG and U266-CG via tail vein. Tumor progression was monitored weekly by bioluminescence imaging (BLI). Mice were divided into three cohorts—tumor bearing untreated (n = 6), tumor bearing treated (n = 6) and no tumor healthy mice (n = 4). The treatment group was injected with bortezomib (1 mg/kg) twice a week intraperitoneally starting at week 1 post-inoculation of MM.1S-CG and U266-CG cells, respectively. Mice were imaged weekly with small animal [¹⁸F]FDG PET and [⁶⁴Cu]Cu-LLP2A PET, respectively